Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Proposes Including Vitamin D With Calcium In Osteoporosis Claims

This article was originally published in The Tan Sheet

Executive Summary

FDA's proposed simplification of the calcium and osteoporosis health claim could encourage more firms in the industry to use the claim in product labeling, the agency states in a proposed rule published in the Jan. 5 Federal Register

You may also be interested in...



FDA Adds Vitamin D To Osteoporosis Risk Reduction Health Claim

Bone-health claims may be made for vitamin D when the nutrient is combined with calcium, according to an FDA final rule

FDA Adds Vitamin D To Osteoporosis Risk Reduction Health Claim

Bone-health claims may be made for vitamin D when the nutrient is combined with calcium, according to an FDA final rule

FDA Adds Vitamin D To Osteoporosis Risk Reduction Health Claim

Bone-health claims may be made for vitamin D when the nutrient is combined with calcium, according to an FDA final rule

Topics

UsernamePublicRestriction

Register

OM002075

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel